P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Sara Bringhen,Peter M. Voorhees,Torben Plesner,Ulf-Henrik Mellqvist,Brandi Reeves,Pieter Sonneveld,Catriona Byrne,Eva Nordström,Johan Harmenberg,Jakob Obermüller,Paul G. Richardson +10 more
TL;DR: Melflufen plus dexamethasone resulted in sustained long‐term clinical benefit in patients with RRMM, according to an updated survival analysis.
Journal ArticleDOI
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
Saad Z. Usmani,Chatchada Karanes,William I. Bensinger,Anita D'Souza,Noopur Raje,Sascha A. Tuchman,Douglas W. Sborov,Jacob P. Laubach,Giada Bianchi,Dheepak Kanagavel,Rao Saleem,Franck Dubin,Frank Campana,Paul G. Richardson +13 more
TL;DR: Part B of this phase 1b study (ClinicalTrialsgov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients as discussed by the authors.
Journal ArticleDOI
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Shambavi Richard,Ajai Chari,Sosana Delimpasi,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryna Kriachok,Meletios A. Dimopoulos,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Ganna Usenko,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Don A. Stevens,Hang Quach,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Ashraf Z. Badros,Larry D. Anderson,Nizar J. Bahlis,Thierry Facon,Maria-Victoria Mateos,Michele Cavo,Hua Chang,Yosef Landesman,Yi Chai,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael Kauffman,Sebastian Grosicki,Paul G. Richardson +37 more
TL;DR: In the phase 3 Boston study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly borthemib-drug examethase (Vd), and XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy,
Journal ArticleDOI
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.
Qingwei Deng,Nicholas Mitsiades,Joseph Negri,Zhaoqin Wen,Melissa Rooney,Teru Hideshima,Dharminder Chauhan,Nikhil C. Munshi,Paul G. Richardson,Francis Y. Lee,Kenneth C. Anderson,Constantine S. Mitsiades +11 more
TL;DR: In vitro, dasatinib significantly suppresses the viability of MM cell lines (including lines resistant to conventional or other novel anti-MM agents); primary tumor specimens from multi-drug resistant MM patients; as well as MM cells co-cultured with BM stromal cells.
Journal ArticleDOI
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma
Sacha N. Uljon,Paul G. Richardson,Peter H. Schur,Peter H. Schur,Kenneth C. Anderson,Milenko J. Tanasijevic,Milenko J. Tanasijevic,Neal I. Lindeman,Neal I. Lindeman +8 more
TL;DR: In 16/17 intact immunoglobulin myeloma patients tested frequently over ~3 years, SFLC performed no better than M-spike and did not add value to conventional serum electrophoresis.